| Headache |
1 |
1 |
| Migraine |
0 |
0.61 |
| Adverse Effects |
0 |
0.6 |
| Monoclonal Antibody |
0 |
0.99 |
| Biologic Therapy |
0 |
0.32 |
| Antiviral Agents |
0 |
0.98 |
| Hepatitis |
0 |
0.3 |
| Immunomodulator |
0 |
0.3 |
| Students |
0 |
0.3 |
| Patient Safety |
0 |
0.25 |
| Hepatitis C Virus |
0 |
0.18 |
| Pulmonary Arterial Hypertension |
0 |
0.18 |
| Artery |
0 |
0.15 |
| Arthritis |
0 |
0.15 |
| Board Certification |
0 |
0.15 |
| Clinical Research |
0 |
0.15 |
| Dorsum |
0 |
0.15 |
| Food and Drug Administration (FDA) |
0 |
0.15 |
| Generics |
0 |
0.15 |
| Grant |
0 |
0.15 |
| New Jersey |
0 |
0.15 |
| Pulmonary Hypertension |
0 |
0.15 |
| Receptors |
0 |
0.15 |
| Weakness |
0 |
0.15 |
| Heart Failure (HF) |
0 |
0.13 |
| Hypertension |
0 |
0.13 |
| Crohn Disease |
0 |
0.11 |
| Asthma |
0 |
0.06 |
| Epilepsy |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Multiple Sclerosis |
0 |
0.06 |
| Psoriasis |
0 |
0.06 |